About Gordian Pharma Ltd
Gordian Pharma was founded in 2020 as a subsidiary of Morvus Technology Limited specifically to exploit Morvus’s MTL-004 by funding it as a separate entity in order to with develop it into a clinic-ready product in as short a time as possible.
Targeting ‘hard to treat’ cancers for which accelerated pre-clinical development was approved by the European Medicines Agency (ICH-S9), Glioblastoma was selected as the primary target, with bladder cancer and lung cancer also considered viable prospects. Glioblastoma is an orphan disease with opportunities to utilise fast-track pathways in the next stage of clinical development.
In addition to approximately £10M spent on the programme by Morvus and others to date, Gordian has invested a further £3.85M of private equity to fund the programme to clinic-readiness.
About MTL-004
MTL-004 is a highly effective, locally acting pro-apoptotic agent designed to induce programmed cell death specifically in the treatment zone. Its unique formulation ensures that it can exert potent effects without causing systemic side effects, making it a promising option for treatments that require precision and minimal toxicity or damage to surrounding tissues.
This localised action allows for enhanced therapeutic outcomes while maintaining patient safety.
Contact Us
For enquiries about our products